Clay Paul
Accounting Internal Assessment |
Jacob Robinson
Marketing External Assessment |
Drew Collins
Accounting Strategy Formulation |
Chelsey Wyman
Accounting Strategy Implementation |
LILLY AT A GLANCE
- A leading pharmaceutical company in the world
- A heritage of more than 135 years strong; company founded on May 10, 1876
- Headquarters located in Indianapolis, Indiana, U.S.A.
- Approximately 38,000 employees worldwide
- More than 7,800 employees engaged in research and development
- Clinical research conducted in more than 55 countries
- Research and development facilities located in eight countries
- Manufacturing plants located in 13 countries
- Products marketed in 125 countries
Evolution of our Big Idea:
Biggest Threat to Eli Lilly and Company: They have a history of drugs being stuck in Phase III drug process. They are not making it all the way through because they are unreliable. So because these drugs are getting stuck in Phase III they have no future product, which causes people not to invest in their company, and to invest in a company that does have future products coming out. So the threat is that Eli Lilly and Company stock is very unstable causing no one to want to invest in their company.
Arrival at Big Idea: The main focus that we have derived at to increase Eli Lilly as a company is to reduce the quantity of drugs and focus more on the quality of drugs we can successfully pass through FDA standards. We are wasting endless amounts of money on marketing and research of the drugs that are being frozen in Phase III the finals phase. We need to increase our marketing by using more advertisement not only for the product but the company name to show how reliable we are. The last part we need to focus on is expanding Elanco Animal Health since they continually grow with the lack of competition in the industry.